Background: Patients with non-functioning renal grafts constitute approximately 4% of patients with incident dialysis. Complete withdrawal of immunosuppression has been associated with a higher risk of HLA sensitization and renal graft intolerance syndrome (GIS).
Methods: We conducted a retrospective observational study of 63 patients with renal graft failure (from January 2012 to December 2022). Immediate graft losses due to vascular thrombosis or technical complications were excluded. We analyzed demographic and clinical characteristics, as well as the evolution of GIS. A comparative study was performed with patients who did not develop GIS (non-GIS).
Results: Twenty-three patients (36.5%) developed GIS. The most common presentation was anemia (73.9%), followed by renal graft pain (65.2%). Seventeen patients (74%) required renal graft embolization. GIS was associated with a higher degree of sensitization. We did not find differences in prior HLA sensitization, causes of graft failure, history of acute rejection, or doses/levels of immunosuppression after graft failure, although rejections were more severe in the GIS group. Patients with GIS had a lower rate of retransplantation after graft failure (4.3% vs 25%, P = .02). Graft failure within the first 2 years after transplantation was the main predictive factor for GIS (hazard ratio = 2.740, 95% confidence interval = 1.06-7.06, P = .03).
Conclusions: GIS was more prevalent in patients who experienced graft failure within the first 2 years. Despite increased immunosuppression, a significant percentage required graft embolization. GIS was associated with an increase in HLA sensitization and a lower likelihood of retransplantation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.transproceed.2024.11.027 | DOI Listing |
J Cardiothorac Surg
January 2025
Department of Cardiothoracic Surgery, Aalborg University Hospital, Hobrovej 18-22, Aalborg, 9000, Denmark.
Background: The outcome of coronary artery bypass grafting (CABG) depends on several factors, including the quality of the distal anastomoses to the coronary arteries. Early graft failure may be caused by, e.g.
View Article and Find Full Text PDFStem Cell Res Ther
January 2025
School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, 10F., Teaching & Research Building, Shuang-Ho Campus, No. 301, Yuantong Rd., Zhonghe Dist., Taipei, 235, Taiwan.
Chronic liver diseases, including cirrhosis and liver failure, remain formidable challenges due to their complex progression and limited therapeutic options. Mesenchymal stem cell (MSC) therapy has emerged as a game-changing approach, leveraging its potent immunomodulatory, anti-fibrotic, and regenerative capabilities, along with the ability to transdifferentiate into hepatocytes. This review delves into the latest advances in MSC-based treatments for chronic and end-stage liver diseases, as highlighted in current clinical trials.
View Article and Find Full Text PDFJ Clin Immunol
January 2025
Population Health Sciences Institute, Newcastle University, Newcastle-Upon-Tyne, UK.
Receptor Interacting Serine/Threonine Kinase 1 (RIPK1) is widely expressed and integral to inflammatory and cell death responses. Autosomal recessive RIPK1-deficiency, due to biallelic loss of function mutations in RIPK1, is a rare inborn error of immunity (IEI) resulting in uncontrolled necroptosis, apoptosis and inflammation. Although hematopoietic stem cell transplantation (HSCT) has been suggested as a potential curative therapy, the extent to which disease may be driven by extra-hematopoietic effects of RIPK1-deficiency, which are non-amenable to HSCT, is not clear.
View Article and Find Full Text PDFNat Rev Nephrol
January 2025
Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.
Sci Rep
January 2025
Department of Surgery, Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, South Korea.
Several donor-specific factors influence the functional recovery and long-term outcomes of liver grafts. This study investigated the association between donor fasting glucose (DFG) and recipient outcomes after living donor liver transplantation (LDLT) in 950 cases at a single center. Patients were divided into two groups: low-DFG (< 85 mg/dL, n = 120) and control (≥ 85 mg/dL, n = 830).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!